GLP-1s unproven effectiveness looks set to spawn a new wave of misleading narratives
Like Ozempic, it requires prior authorization and documentation of previous medication trials
In the IMPACT trial, pemvidutide achieved mean weight losses of 4.8% and 5.8% with 1.2 and 1.8 mg doses respectively at 24 weeks, compared to 0.5% with placebo, with weight loss curves showing no evidence of plateauing, suggesting continued benefit with longer treatment [49-51]
Increasing the weight or resistance level (e.g., using slightly heavier dumbbells or a thicker resistance band)
It turned out to be a truncated form of the predicted GLP-1, starting with residue no 78 and thus cleaved at a monobasic site
This notion is speculative at present, as no change in cognition was observed in one small RCT of exenatide in schizophrenia 140 , while a positive cognitive effect of liraglutide was only seen in an even smaller non-randomized open-label investigation of people with either depressive or bipolar disorders 178,179